Oksana A Shlobin
Overview
Explore the profile of Oksana A Shlobin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1845
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robbins E, Bradley K, Badesch D, Burger C, Chybowski A, De Marco T, et al.
Ann Am Thorac Soc
. 2025 Feb;
PMID: 39965160
Pulmonary arterial hypertension (PAH) is associated with significant morbidity and mortality. The extent of medication non-adherence in PAH is uncertain and may be linked to adverse outcomes. There has been...
2.
Nathan S, Kim H, King C, Aryal S, Thomas C, Kattih Z, et al.
Am J Respir Crit Care Med
. 2025 Feb;
PMID: 39928362
Rationale: Pulmonary hypertension (PH) commonly complicates idiopathic pulmonary fibrosis (IPF). However, the rate of change in pulmonary hemodynamics in IPF remains poorly defined. Objectives: To examine the rate of change...
3.
Vaidya A, Sketch M, Broderick M, Shlobin O
BMC Pulm Med
. 2024 Nov;
24(1):574.
PMID: 39567921
Background: Current clinical guidelines support use of parenteral prostacyclin therapy for patients with pulmonary arterial hypertension (PAH) at intermediate risk. The objective of this study was to assess parenteral prostacyclin...
4.
Raina A, Sketch M, Wu B, Broderick M, Shlobin O
Pulm Circ
. 2024 Oct;
14(4):e12455.
PMID: 39431235
The objective of this analysis was to compare clinician-based and formally calculated risk assessments by REVEAL Lite 2 and COMPERA 2.0 and to characterize parenteral prostacyclin utilization within 90 days...
5.
Shlobin O, Bruce G, Gomez-Rendon G, Kingman M, Rahman M, Rogers F, et al.
Pulm Circ
. 2024 Oct;
14(4):e12441.
PMID: 39398324
This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and...
6.
Sitbon O, Skride A, Feldman J, Sahay S, Shlobin O, McLaughlin V, et al.
Lancet Respir Med
. 2024 Sep;
12(11):865-876.
PMID: 39307144
Background: The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data strongly indicating involvement in disease pathogenesis; however, clinical studies have yielded...
7.
Shlobin O, Adir Y, Barbera J, Cottin V, Harari S, Jutant E, et al.
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209469
Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common and underrecognised. The presence of PH in the setting of lung disease has been consistently shown to be...
8.
Harder E, Nardelli P, Pistenmaa C, Ash S, Balasubramanian A, Bowler R, et al.
Am J Respir Crit Care Med
. 2024 May;
210(9):1132-1142.
PMID: 38820122
Quantitative interstitial abnormalities (QIAs) are a computed tomography (CT) measure of early parenchymal lung disease associated with worse clinical outcomes, including exercise capacity and symptoms. The presence of pulmonary vasculopathy...
9.
Khan S, Danoff S, Kulkarni T, Reichuber J, Shifren A, Shlobin O, et al.
Ann Am Thorac Soc
. 2024 Apr;
21(7):1103-1106.
PMID: 38626420
No abstract available.
10.
King C, Ignacio R, Khangoora V, Nyquist A, Singhal A, Thomas C, et al.
Am J Respir Crit Care Med
. 2024 Jan;
210(6):801-813.
PMID: 38236191
Little is known about hospitalization in other types of interstitial lung disease (ILD) besides idiopathic pulmonary fibrosis (IPF). To determine the frequency of hospitalizations in various types of ILD and...